315 related articles for article (PubMed ID: 28857489)
1. Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size.
Kim HI; Kim TH; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim YN; Kim H; Ahn HS; Kim K; Kim SW; Chung JH
Cancer Med; 2017 Oct; 6(10):2244-2251. PubMed ID: 28857489
[TBL] [Abstract][Full Text] [Related]
2. Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis.
Kim HI; Kim K; Park SY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn HS; Kim SW; Kim TH; Chung JH
Oral Oncol; 2018 Mar; 78():80-86. PubMed ID: 29496063
[TBL] [Abstract][Full Text] [Related]
3. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.
Back K; Kim TH; Lee J; Kim JS; Choe JH; Oh YL; Cho A; Kim JH
J Pediatr Surg; 2023 Mar; 58(3):568-573. PubMed ID: 35973863
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
5. The prognostic factors for clinical N1b patients in thyroid papillary carcinoma.
Yuksel UM; Turanli S; Acar Y; Berberoglu U
J Cancer Res Ther; 2019; 15(3):681-685. PubMed ID: 31169240
[TBL] [Abstract][Full Text] [Related]
6. Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.
Lee SG; Ho J; Choi JB; Kim TH; Kim MJ; Ban EJ; Lee CR; Kang SW; Jeong JJ; Nam KH; Jung SG; Jo YS; Lee J; Chung WY
Medicine (Baltimore); 2016 Feb; 95(5):e2692. PubMed ID: 26844509
[TBL] [Abstract][Full Text] [Related]
7. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
Kim M; Kim HK; Kim HI; Kim EH; Jeon MJ; Yi HS; Kim ES; Kim H; Kim TH; Kim BH; Kim TY; Kang HC; Kim WB; Chung JH; Shong YK; Kim SW; Kim WG
Oral Oncol; 2018 Nov; 86():48-52. PubMed ID: 30409319
[TBL] [Abstract][Full Text] [Related]
8. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
[TBL] [Abstract][Full Text] [Related]
9. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
[TBL] [Abstract][Full Text] [Related]
11. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
12. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for level V metastasis in patients with N1b papillary thyroid cancer.
Kang JG; Choi JE; Kang SH
World J Surg Oncol; 2022 Sep; 20(1):327. PubMed ID: 36180912
[TBL] [Abstract][Full Text] [Related]
14. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
15. Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer.
Wang LY; Palmer FL; Nixon IJ; Tuttle RM; Shah JP; Patel SG; Shaha AR; Ganly I
Ann Surg Oncol; 2015 Oct; 22(11):3530-6. PubMed ID: 25665952
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.
Tavarelli M; Sarfati J; Chereau N; Tissier F; Golmard JL; Ghander C; Lussey-Lepoutre C; Trésallet C; Menegaux F; Leenhardt L; Buffet C
Thyroid; 2017 Jun; 27(6):778-786. PubMed ID: 28351220
[TBL] [Abstract][Full Text] [Related]
17. Effect of skip metastasis to lateral neck lymph nodes on outcome of patients with papillary thyroid carcinoma.
Bertin JB; Buffet C; Leenhardt L; Menegaux F; Chereau N
Langenbecks Arch Surg; 2022 Nov; 407(7):3025-3030. PubMed ID: 35819485
[TBL] [Abstract][Full Text] [Related]
18. Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome.
Sapuppo G; Palermo F; Russo M; Tavarelli M; Masucci R; Squatrito S; Vigneri R; Pellegriti G
J Endocrinol Invest; 2017 Dec; 40(12):1355-1363. PubMed ID: 28646475
[TBL] [Abstract][Full Text] [Related]
19. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for recurrent disease in small papillary thyroid cancers - a Swedish register-based study.
Bayadsi H; Nylén C; Sandström M; Angelsten J; Sund M; Hennings J
Langenbecks Arch Surg; 2023 Apr; 408(1):162. PubMed ID: 37099203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
